Ivonescimab Secures Second Phase III Triumph, Redefining Standard of Care in Biliary Tract Cancer and Bolstering Global Oncology Ambitions

SHANGHAI/CAMBRIDGE, MA – [Date] – In a significant development for oncology, Ivonescimab, the innovative PD-1 x VEGF bispecific antibody, has achieved its second pivotal Phase III success, demonstrating superior efficacy in a Chinese study for frontline, advanced biliary tract cancer (BTC). This latest victory, announced by its developer Akeso, not only marks Ivonescimab’s first Phase III win in a gastrointestinal oncology indication but also profoundly strengthens Summit Therapeutics’ audacious $500 million upfront investment, potentially validating its bet on the drug’s global mega-blockbuster potential.

n

The late-stage triumph stems from the Akeso-sponsored HARMONi-GI1 study (NCT06591520), which pitted a combination of ivonescimab and chemotherapy against AstraZeneca’s established immune checkpoint inhibitor, Imfinzi (durvalumab), alongside chemotherapy, in patients with advanced BTC. An eagerly anticipated pre-specified interim analysis revealed that the ivonescimab regimen delivered statistically significant and clinically meaningful improvements in overall survival (OS), the study’s primary endpoint, effectively surpassing one of the current standards of care. This success further solidifies the drug’s profile, which is already under US regulatory review for non-small cell lung cancer (NSCLC), signalling a broad and impactful future across multiple solid tumour indications.

n

A New Horizon for Biliary Tract Cancer Treatment

n

Biliary tract cancer (BTC) represents a group of aggressive and often fatal malignancies arising from the bile ducts. These cancers, which include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, are notoriously difficult to diagnose early due to their non-specific symptoms and anatomical location. Consequently, most patients are diagnosed at an advanced or metastatic stage, where prognosis is grim and treatment options are limited. The global incidence of BTC is rising, particularly in certain regions, underscoring the urgent need for more effective therapeutic strategies.

n

Historically, the standard of care for advanced BTC has revolved around systemic chemotherapy, primarily combinations of gemcitabine and cisplatin. While these regimens offer some survival benefit, the median overall survival typically ranges from 10 to 12 months, highlighting a substantial unmet medical need. The landscape has recently begun to evolve with the introduction of immune checkpoint inhibitors (ICIs). Specifically, the combination of gemcitabine and cisplatin with ICIs like AstraZeneca’s Imfinzi (durvalumab) or MSD’s Keytruda (pembrolizumab) has emerged as a preferred frontline option, based on data demonstrating modest yet significant survival advantages over chemotherapy alone. The HARMONi-GI1 study’s direct comparison against an Imfinzi-containing regimen therefore represents a stringent and highly relevant test of Ivonescimab’s capabilities.

n

The HARMONi-GI1 study’s design was robust, enrolling patients with frontline, advanced BTC across multiple centers in China. The primary objective was to assess overall survival (OS), the gold standard endpoint in oncology clinical trials, reflecting the true longevity benefit for patients. The successful achievement of this primary endpoint at an interim analysis is particularly noteworthy, often indicating a substantial treatment effect that warrants early reporting and potentially accelerated regulatory pathways.

n

Beyond overall survival, the ivonescimab-chemotherapy combination also met its key secondary endpoints, showcasing significant improvements in progression-free survival (PFS) and objective response rates (ORR). Progression-free survival measures the length of time a patient lives with the disease without it getting worse, providing an important early indicator of efficacy. Objective response rate, which quantifies the percentage of patients whose tumors shrink or disappear in response to treatment, speaks to the immediate anti-tumor activity of the drug. The confluence of positive outcomes across OS, PFS, and ORR paints a compelling picture of Ivonescimab’s superior clinical profile, suggesting a more profound and durable anti-cancer effect compared to existing immunochemotherapy options.

n

The companies involved, Akeso and Summit Therapeutics, have indicated that detailed results from the HARMONi-GI1 study are anticipated to be presented at an upcoming major international medical conference. Such presentations are crucial for peer review, further scientific discourse, and to provide granular data on safety, specific patient populations benefiting most, and the magnitude of the observed survival gains. This transparency will be vital for global regulatory submissions and for informing clinical practice.

n

The Science Behind the Success: A Dual-Action Bispecific Antibody

n

Ivonescimab, also known as AK112, is a novel bispecific antibody that simultaneously targets two critical pathways implicated in cancer progression: programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). This dual mechanism of action is central to its therapeutic promise and potential superiority over monotherapies or combinations of separate monoclonal antibodies.

n

PD-1 Inhibition: The PD-1/PD-L1 pathway is a well-established immune checkpoint that cancer cells exploit to evade immune surveillance. By blocking PD-1, Ivonescimab aims to "release the brakes" on the immune system, particularly cytotoxic T-cells, enabling them to recognize and attack tumor cells more effectively. This mechanism is the cornerstone of modern immunotherapy, responsible for the success of drugs like pembrolizumab (Keytruda) and durvalumab (Imfinzi).

n

VEGF Inhibition: Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis, the process by which new blood vessels are formed. Tumors rely heavily on angiogenesis to supply themselves with oxygen and nutrients, facilitating their growth and metastasis. By inhibiting VEGF, Ivonescimab aims to starve the tumor by cutting off its blood supply, thereby hindering its proliferation and spread. This anti-angiogenic approach has also been successfully employed in oncology with drugs like bevacizumab.

n

The innovative aspect of Ivonescimab lies in its bispecific design, integrating both functions into a single molecule. This simultaneous targeting is hypothesized to offer synergistic benefits that may be superior to administering two separate monoclonal antibodies. Potential advantages include:

n

n
• Enhanced Tumor Penetration: A single molecule might achieve more efficient co-localization and binding at the tumor site, where both PD-1 expressing immune cells and VEGF-producing tumor cells/stromal cells are present.

n

• Optimized Pharmacokinetics: A bispecific antibody may have a more favorable pharmacokinetic profile, potentially simplifying dosing regimens and reducing the overall drug burden.

n

• Broader Anti-Tumor Activity: By addressing both immune evasion and tumor vascularization simultaneously, Ivonescimab could potentially overcome resistance mechanisms that might emerge with single-pathway inhibition. For instance, VEGF inhibition has been shown to normalize tumor vasculature, which can improve the delivery and efficacy of immune cells and other anti-cancer agents to the tumor microenvironment. Conversely, immune activation might also influence the tumor’s angiogenic profile.

n

• Potentially Improved Safety Profile: While combining two mechanisms, the single molecule design might, in some cases, lead to a more manageable safety profile compared to the potential additive toxicities of two distinct agents.

n

n

This dual-targeting strategy positions Ivonescimab as a next-generation oncology therapeutic, designed to tackle the complex biology of cancer from multiple angles, leading to more profound and durable responses.

n

Summit Therapeutics’ Visionary Investment Pays Off

n

The latest Phase III success in BTC serves as a powerful validation of Summit Therapeutics’ bold strategic move in 2022. The US-based biopharmaceutical company committed an eye-watering $500 million upfront payment, with potential milestone payments reaching up to $5 billion, to secure exclusive rights to Ivonescimab in major global markets including the US, Europe, Canada, Japan, Latin America, the Middle East, and Africa. This colossal investment underscored Summit’s conviction in the drug’s transformative potential, effectively reshaping its entire pipeline and strategic direction.

n

For Summit, Ivonescimab represents a cornerstone asset. Prior to this deal, the company’s pipeline was relatively nascent. The acquisition of Ivonescimab rights from Akeso, a leading Chinese biopharmaceutical company, was a high-stakes gamble that hinged on the drug’s ability to replicate its initial promising data from China in rigorous global trials and regulatory environments. The previous Phase III success of Ivonescimab in NSCLC in China, which led to its initial approval there, likely provided the initial impetus and confidence for Summit’s substantial financial commitment.

n

This recent BTC win, particularly its performance against a current standard of care, significantly de-risks Summit’s investment. It signals that Ivonescimab’s efficacy is not limited to lung cancer or specific patient populations but extends to other challenging solid tumors, broadening its market potential and strengthening its competitive edge. The ability of a drug developed primarily in China to achieve such robust results in a globally relevant oncology indication also speaks volumes about the quality of Akeso’s research and development capabilities.

n

Navigating Global Regulatory Pathways

n

Ivonescimab’s journey through regulatory bodies is multi-faceted. In China, Akeso has already secured approval for Ivonescimab in non-small cell lung cancer (NSCLC), marking a significant milestone for the drug and for Akeso as an innovator. This initial approval provided a strong foundation for its global ambitions.

n

For Summit Therapeutics, the immediate focus in the Western markets is the ongoing US regulatory review for Ivonescimab in NSCLC. The US Food and Drug Administration (FDA) is currently deliberating on the drug’s future on the American NSCLC market. A positive decision from the FDA would not only be a monumental achievement for Summit but also a critical step towards establishing Ivonescimab as a leading oncology therapeutic in the world’s largest pharmaceutical market. The FDA’s decision is highly anticipated and will be a key determinant of Summit’s near-term trajectory and the broader market perception of Ivonescimab.

n

The recent HARMONi-GI1 data in BTC introduces a new dimension to these regulatory efforts. Following the successful interim analysis, Akeso is expected to move swiftly towards filing for regulatory approval in China for Ivonescimab in BTC. This would potentially make BTC the second approved indication for the drug in its home market. For Summit, the positive BTC data, while from a Chinese study, offers compelling evidence that could support future global development and regulatory strategies. Depending on the specifics of the data and discussions with regulatory bodies like the FDA and European Medicines Agency (EMA), this success could potentially:

n

n
• Accelerate Global BTC Programs: Prompt Summit to initiate or accelerate its own global Phase III trials for Ivonescimab in BTC, leveraging the strong proof-of-concept from HARMONi-GI1.
• Inform Label Expansion: If approved in NSCLC, this data could support future label expansion efforts into BTC in Western markets, potentially through bridging studies or as part of broader basket trials.
• Strengthen Overall Profile: The consistent efficacy across different tumor types reinforces the drug’s general potential and could positively influence regulatory bodies’ overall perception of Ivonescimab’s benefit-risk profile.

The successful navigation of these diverse regulatory landscapes, balancing regional approvals with global development, will be crucial for Ivonescimab to realize its full market potential.

A Widespread Solid Tumor Program: Ivonescimab’s Ambitious Reach

The latest success in BTC is not an isolated event but rather a testament to Ivonescimab’s widespread development program across a multitude of challenging solid tumor indications. This extensive clinical pipeline underscores the belief that its dual-targeting mechanism holds broad applicability in oncology.

Summit Therapeutics, leveraging its global rights, has initiated several frontline programs for Ivonescimab in key indications beyond the initial NSCLC focus. These include:

• Various Subsets of Non-Small Cell Lung Cancer (NSCLC): Building on its foundational success, Summit is exploring Ivonescimab in different lines of therapy and patient populations within NSCLC to maximize its impact.
• Head and Neck Squamous Cell Carcinoma (HNSCC): HNSCC is another aggressive cancer with significant unmet needs, where immunotherapy has shown promise but often requires further enhancement.
• Colorectal Cancer (CRC): CRC remains a leading cause of cancer-related deaths globally, and new, more effective first-line options are desperately needed, especially for advanced metastatic disease.

Concurrently, Akeso continues to advance Ivonescimab through its own mid-to-late-stage studies in China for several other challenging solid tumor indications. These include:

• Ovarian Cancer: A gynecological cancer often diagnosed at advanced stages with high recurrence rates.
• Triple-Negative Breast Cancer (TNBC): An aggressive subtype of breast cancer notoriously difficult to treat due to the lack of targeted receptors.
• Hepatocellular Carcinoma (HCC): The most common form of liver cancer, often associated with chronic liver disease and poor prognosis.

This broad-spectrum approach positions Ivonescimab not merely as a drug for a single cancer type but as a potential "pipeline in a product," capable of addressing significant unmet needs across numerous oncology indications. Each successful trial expands the drug’s market opportunity and reinforces its value proposition.

Market Impact and Future Outlook: A Mega-Blockbuster in the Making

The robust clinical data emerging from Ivonescimab’s trials, particularly the recent BTC win, strongly supports the consensus forecast from GlobalData, the parent company of Clinical Trials Arena. According to their projections, Ivonescimab is poised to achieve "mega-blockbuster" status, with sales expected to exceed an astounding $9 billion by 2032.

A "mega-blockbuster" drug is defined by its exceptional sales performance, typically surpassing $5 billion annually, signifying profound market penetration and clinical impact. Several factors contribute to this ambitious forecast for Ivonescimab:

• Broad Indication Portfolio: Success across multiple, high-incidence solid tumors (NSCLC, BTC, HNSCC, CRC, etc.) will create a vast addressable patient population.
• Superior Efficacy: The consistent demonstration of improved overall survival, progression-free survival, and objective response rates over existing standards of care positions Ivonescimab as a front-runner in efficacy.
• First-Line Potential: The ability to be used in the first-line setting, as demonstrated in both NSCLC and now BTC, allows the drug to capture a larger segment of the newly diagnosed patient population, maximizing its revenue potential.
• Differentiated Mechanism: The unique PD-1 x VEGF bispecific mechanism offers a clear differentiation from existing immunotherapies and anti-angiogenics, potentially leading to better outcomes in patients who may not respond optimally to single-pathway agents.
• Global Reach: Summit’s extensive licensing agreement covering major pharmaceutical markets ensures a widespread commercial footprint.

The potential for Ivonescimab to reach such sales figures implies a significant disruption to the oncology market. It could shift treatment paradigms, particularly in areas like BTC where treatment options are limited, and potentially redefine the standard of care in other indications where it eventually gains approval. For patients, this translates into the promise of more effective, potentially life-extending therapies. For healthcare systems, it represents a new, high-value therapeutic option, albeit one that will likely come with a premium price tag, necessitating careful considerations regarding access and reimbursement.

The success of bispecific antibodies like Ivonescimab also highlights a broader trend in oncology research: the move towards more sophisticated, multi-targeted therapies designed to overcome the complex and redundant pathways that drive cancer growth and resistance. As more bispecific and multi-specific antibodies enter late-stage development, they are poised to become a dominant force in the next wave of cancer therapeutics.

Conclusion

The second Phase III victory for Ivonescimab, specifically in the challenging landscape of advanced biliary tract cancer, marks a pivotal moment in its development journey. This success not only validates Summit Therapeutics’ substantial investment and strategic vision but also underscores the transformative potential of Ivonescimab’s innovative PD-1 x VEGF bispecific mechanism.

With its widespread solid tumor program, ongoing US regulatory review for NSCLC, and now compelling data in BTC, Ivonescimab is rapidly emerging as a leading contender in the global oncology arena. As the detailed HARMONi-GI1 results await presentation and regulatory decisions loom, the medical community and industry alike will be keenly watching Ivonescimab’s continued progress, anticipating its potential to redefine therapeutic paradigms and offer new hope to patients battling some of the most aggressive and difficult-to-treat cancers. The path to becoming a mega-blockbuster is clearer than ever for this promising dual-action antibody.